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HIV-1-specific antibodies and CD8+ cytotoxic T cells are detected in most HIV-1-infected people, yet HIV-1
infection is not eradicated. Contributing to the failure to mount a sterilizing immune response may be the
inability of antigen-presenting dendritic cells (DCs) to sense HIV-1 during acute infection, and thus the
inability to effectively prime naive, HIV-1-specific T cells. Recent findings related to DC-expressed innate
immune factors including SAMHD1, TREX1, and TRIM5 provide a molecular basis for understanding why
DCs fail to adequately sense invasion by this deadly pathogen and suggest experimental approaches to
improve T cell priming to HIV-1 in prophylactic vaccination protocols.Currently, more than 30 drug formulations are approved that
block HIV-1 replication and prevent infected individuals from
progressing to AIDS (http://www.fda.gov). However, treatment
with these drugs is lifelong and plagued with toxicity, virus-
drug resistance, and significant economic cost. According to
recent figures from UNAIDS, 34 million people are infected
with HIV-1, and for each person who starts anti-HIV-1 drug treat-
ment, it is estimated that there are 2–3 new infections. In 2010,
1.8 million people died of AIDS-related illnesses and 2.6 million
became infected with HIV-1. Efforts to control the AIDS
pandemic would benefit from an effective anti-HIV-1 vaccine,
but with perhaps one exception (Rerks-Ngarm et al., 2009),
attempts to prevent new HIV-1 infection in human vaccine trials
have been unsuccessful.
The eradication of smallpox and the effective control of polio-
virus, measles, mumps, rubella, and yellow fever offer stark
contrast to the public health experience with HIV-1. The live virus
preparations used to immunize against these pathogens were
developed empirically, without understanding the mechanisms
that underlie the anamnestic response. The success of the
vaccines against these viruses—particularly those vaccines
that replicate within the host—demonstrates that lifelong protec-
tive immune responses can be elicited by vaccination.
In contradistinction, people infected with HIV-1 progress to
AIDS despite measurable humoral and cellular immune
responses to HIV-1 (Virgin and Walker, 2010). Worse still,
HIV-1-infected people with documented, broad anti-HIV-1
immune responses can be secondarily infected with HIV-1 (Alt-
feld et al., 2002; Smith et al., 2005). Interestingly, failure to
protect against reinfection is also seen with Hepatitis C virus
(Blackard and Sherman, 2007), and no vaccine is available for
this virus either. These observations do not mean that an
HIV-1 prophylactic vaccine is impossible, especially given
that superinfection with HIV-1 might be aided by the immune
dysfunction associated with prior HIV-1 infection. Nonetheless,
these observations demonstrate that the immune response
targeting HIV-1 differs fundamentally from that against the
viruses described above and suggest that, in the absence of
some fundamental modification in vaccine design, even a live
vaccine would be unlikely to alter the outcome of an HIV-1
challenge.408 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.While failure to elicit protective immunity distinguishes HIV-1
(and HCV) from pathogenic viruses such as poliovirus and
measles, these are not the only viruses that have eluded efforts
to develop a protective vaccine. Dengue infects 500 million
people each year, two million of whom suffer complications of
hemorrhagic fever (Beatty et al., 2010). Like HIV-1, there are
multiple types of Dengue virus, there is no good animal model,
and there are no simple correlates of immunologic protection.
The first protective Dengue vaccine—albeit with 30% effi-
cacy—was possible only recently, after 50 years of research
(Sabchareon et al., 2012). These results are remarkably similar
to the reported 31% efficacy in RV144, the only successful
HIV-1 prophylactic vaccine trial (Rerks-Ngarm et al., 2009).
Respiratory Syncytial Virus (RSV) causes >100,000 hospitali-
zations for pneumonia each year in the United States (Welliver,
2003). As with HIV-1, RSV-specific immune responses are
detectable after infection, but protection against recurrent infec-
tion is not conferred. Attempts to vaccinate against RSV even
caused a paradoxical increase in disease severity, perhaps
because the particular adjuvant used—alum—elicited a nonpro-
tective CD4+ TH2 response (Lindell et al., 2011). Ultimately, any
advance in mechanistic understanding of protective immunity
targeting HIV-1 would likely benefit attempts to control Dengue
virus, RSV, and other viruses as well.
This reviewwill assess the large body of literature onHIV-1 and
construct a model to explain why the human immune system
fails to eliminate or prevent HIV-1 infection. In large part, it will
focus on recent developments regarding host cell restriction
factors and attempt to link these findings to what is known about
innate immune detection of HIV-1, T cell priming by DCs, and
HIV-1 vaccine development.
What Permits HIV-1 to Escape Control by the Human
Immune System?
Several hypotheses offer plausible explanations for HIV-1 persis-
tence in the face of apparent antiviral immunity. Soon after
establishment of infection by one or a few HIV-1 virions, variants
are selected in response to pressure from HIV-1-specific cyto-
toxic T lymphocytes (CTLs) and neutralizing antibody (Kearney
et al., 2009; Henn et al., 2012). It should be noted that high muta-
genic rates and complex mixtures of sequence variants known
Figure 1. Dendritic Cells Provide Multiple
Signals to Naive T Cells
The innate immune system instructs the acquired
immune system via a diverse set of signals that
dendritic cells provide to naive, antigen-specific
T cells. A range of outcomes are possible, from
tolerance to potent antiviral immunity, depending
upon the exact signals provided. Protective anti-
viral immunity requires that naive T cells specific
for viral antigens receive three signals from DCs
(Reis e Sousa, 2006). Elaboration of the three
signals requires DC maturation, most effectively
attained by activation of cell-intrinsic pattern
recognition receptors. The first signal involves
antigen presentation via MHC. The second signal
is provided by cell surface molecules that include CD80 and CD86. The third signal is delivered by cytokines that include IL-12, the structure of which is shown
(PDB: 1F45) (Yoon et al., 2000); the two IL-12 subunits are distinguished from each other by red (IL12A, p35) and blue (IL12B, p40).
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including some viruses for which there are effective vaccines.
The pathogenesis of poliovirus, for example, requires an error-
prone viral polymerase and the quasi-species that it generates
(Vignuzzi et al., 2006). This suggests that it is not quasi-species
per se that distinguishes HIV-1 from other viruses, but rather
HIV-1’s capacity to replicate in the face of enormous sequence
variation.
The HIV-1 Env glycoprotein, in particular, is distinguished by
great sequence diversity and conformational flexibility, as well
as an extensive glycan shield and viral entry receptor binding
sites that are well concealed and only accessible to antibodies
that have undergone extensive somatic mutation (Zhou et al.,
2007; Scheid et al., 2009; Bar et al., 2012). Details about this
extraordinary molecule and how broadly neutralizing antibodies
might be generated by prophylactic vaccination is discussed in
an accompanying review by Dennis Burton and colleagues
(Burton et al., 2012).
Another intuitive explanation for the inability of the immune
system to clear infection is that HIV-1 inactivates the same cells
of the immune system that protect against viral infection. But
tropism for immune cells, as well as the immunosuppression
that results, is shared with viruses such as the measles virus,
for which an effective vaccine exists (Tatsuo et al., 2000).
Perhaps what is critical for HIV-1 persistence is the exact
subclass of immune cell targeted by HIV-1 (Chomont et al.,
2009) or the selective targeting of HIV-1-specific CD4+ T cells
(Douek et al., 2002).
Importantly, like all retroviruses, HIV-1 integrates its genome
into host cell chromosomal DNA, where the virus becomes a
permanent genetic element in the infected cell and in all daughter
cells. This enables it to establish a reservoir of HIV-1-infected
cells that persist indefinitely, even in the face of an otherwise
effective immune response. In contrast, measles virus cannot
integrate, it cannot establish a latent reservoir of infection, and
it cannot persist after the measles virus-specific immune
response is established.
Histone deacetylase (HDAC) inhibitors activate latent HIV-1
provirus transcription and have been touted as ameans to purge
the latent reservoir of HIV-1-infected cells (Archin et al., 2012).
The underlying idea is that, upon transcriptional activation of
latent HIV-1 proviruses, HIV-1 proteins will be synthesized that
would render these infected cells detectable by HIV-1-specific
cytotoxic T cells. However, upon activation of transcription bythe HDAC inhibitors, the HIV-1-infected cells were not killed by
autologous, HIV-1-specific CTL unless the CTL were stimulated
with cognate antigen prior to provirus reactivation (Shan et al.,
2012). These experiments demonstrate that the HIV-1-specific
CTL responses in these individuals were somehow defective.
DC Maturation and Priming of Naive T Cells
Recent research on HIV-1 interaction with dendritic cells (DCs)
suggests another hypothesis to explain HIV-1 persistence.
DCs are highly heterogeneous, antigen-presenting cells that
initiate acquired immune responses by priming naive, antigen-
specific T cells (Steinman and Idoyaga, 2010). The nature of
the T cell response that ensues, whether tolerance or sterilizing
antiviral immunity, is determined by the maturation status of
the antigen-presenting DC and the array of signals that the DC
provides to the naive, antigen-specific T cell (Figure 1). Among
the molecules relevant to T cell priming that DCs elaborate in
response to maturation are cell surface MHC Class II, CD80
and CD86, and cytokines such as IL-12 that promote TH1
responses and the cytotoxic T lymphocytes that clear virus-
infected cells (Reis e Sousa, 2006; Altfeld et al., 2011).
DCs mature when pattern recognition receptors (PRRs) are
stimulated by pathogen-associatedmolecular patterns (PAMPS)
(Akira et al., 2006). Viruses are obligate intracellular parasites,
largely dependent upon host cell machinery for replication.
They therefore do not generate completely foreign molecules
like lipopolysaccharide that distinguish them from the host.
Instead, PRRs alert cells to the presence of viruses by detecting
more subtle features such as structured replication intermedi-
ates, modified nucleic acids, or viral replication complexes in
cellular compartments where nucleic acids are not normally
found.
Viral nucleic acids can be detected via cell-extrinsic or cell-
intrinsic mechanisms (Iwasaki and Medzhitov, 2010). The former
include TLR activation after phagocytosis of virus-infected,
apoptotic cells. Such extrinsic PRRs are not expressed by all
cell types but are generally restricted to antigen-presenting or
phagocytic cells, such as dendritic cells. Cell intrinsic mecha-
nisms detect viral nucleic acid within the infected cell, and the
PRRs that detect these PAMPs are generally expressed on
a broad range of cell types, including fibroblasts. RIG-I and
MDA-5 are cell intrinsic cytosolic receptors that detect structural
features unique to viral RNA. A cell-intrinsic mechanism also
exists for detecting viral DNA in the host cell cytoplasm.Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 409
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and AIM2 (Unterholzner et al., 2010; Sharma and Fitzgerald,
2011; Sharma et al., 2011; Zhang et al., 2011; Li et al., 2012;
Upton et al., 2012).
Optimal priming of naive T cells to generate potent CD4+ TH1
and CD8+ cytotoxic T cell responses requires that PAMP recog-
nition by PRRs occur within the same DCs that present the
antigen, at least under particular experimental conditions (Spo¨rri
and Reis e Sousa, 2005; Hou et al., 2008; Kratky et al., 2011).
Separation of antigen presentation from PAMP recognition and
DC maturation may result in expansion of antigen-specific
T cells that lack potent antiviral activity. It is in fact well described
that HIV-1-specific T cells express elevated levels of inhibitory
molecules such as PD-1, TRAIL, and CTLA-4 (Day et al., 2006;
Trautmann et al., 2006; Wherry et al., 2007).
Complicating the assessment of these inhibitory molecules on
the HIV-1-specific CD8+ T cells is that these samemolecules are
upregulated on activated T cells. Coexpression of PD-1 with
another negative regulator of T cell activation, CD160, distin-
guishes a subset of ineffective HIV-1-specific CD8+ T cells
from activated T cells (Peretz et al., 2012). While these ineffec-
tive, HIV-1-specific, CD8+ T cells are thought to reflect a state
of immune exhaustion that arises during chronic infection with
HIV-1 (Khaitan and Unutmaz, 2011), similar phenotypes are
observed in short-term experiments ex vivo and in humanized
mice (Brainard et al., 2009; Lubong Sabado et al., 2009; Che
et al., 2010), suggesting that T cell priming to HIV-1 antigens in
the absence of optimal DC maturation might contribute to these
ineffective, anti-HIV-1 immune responses.
Innate Immune Detection of Retroviruses
Innate immune detection of viral nucleic acid generally activates
type 1 interferon (IFN) and a large number of IFN-stimulated
genes with a range of antiviral effector functions. Type 1 IFN
also promotes DC maturation and contributes to potent antiviral
T cell responses (Longhi et al., 2009). Retroviruses normally do
not induce type 1 IFN, perhaps because the level of viral nucleic
acid is kept at low level, or because the retrovirus genome is
inaccessible to intrinsic PRRs (Fonteneau et al., 2004; Smed-
So¨rensen et al., 2004; Beignon et al., 2005; Yan et al., 2010; Lib-
eratore and Bieniasz, 2011). This has made it difficult to deter-
mine if the innate immune system is capable of detecting
retroviruses, and it explains why the study of innate immunity
against retroviruses has lagged behind that of other viruses.
Unlike other viruses that do induce type 1 IFN, retroviruses are
generally believed not to encode specific proteins that block
innate immune signaling, although some recent reports suggest
that HIV-1 disrupts RIG-I and a downstream transcription factor,
interferon regulatory factor (IRF3) (Solis et al., 2011; Doehle et al.,
2012a, 2012b). Further, under particular experimental conditions
in vitro, aborted HIV-1 reverse transcripts in CD4+ T cells have
been shown to activate apoptosis and inflammation in a process
that involves caspase-3 and caspase-1 (Doitsh et al., 2010).
Important information concerning innate immune detection of
retroviruses has been obtained by studying rare instances where
adaptive immune control of retroviral infection has been
observed. Specific strains of inbred mice such as I/LnJ and
C57BL/6J, for example, are resistant to infection with the murine
retroviruses Murine Leukemia Virus (MuLV) and Mouse410 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.Mammary Tumor Virus (MMTV) via both humoral and cellular
mechanisms. This experimental system offers an opportunity
to identify the innate immune PRRs that contribute to these
protective, antiretroviral acquired immune responses. The pro-
tective antibody responses to both viruses in these mice were
TLR7 dependent (Kane et al., 2011b), but induction of protective
CTL responses was dependent on a separate, yet to be defined,
innate immune detection pathway (Browne and Littman, 2009;
Kane et al., 2011b).
The importance of innate immune detection of retroviruses for
subsequent acquired immunity was also demonstrated in exper-
iments concerning the influence of the route of infection. When
transmitted to pups via ingestion of mother’s milk, MMTV
acquires a coat of LPS derived from intestinal bacteria (Kane
et al., 2011a). Upon engulfment of these virions by the host cells,
TLR4 signaling was activated by the virion-associated LPS. The
subsequent cascade of signals resulted in production of IL-10,
a tolerogenic cytokine that permitted chronic infection. When
MMTV was ingested following sterilization of gut bacteria, or
when MMTV infection was initiated parenterally, tolerance to
the virus was not observed, and chronic infection did not ensue.
HIV-1 Sensing by DCs
Several types of DCs have been described, though they can be
divided into twomajor groups, the myeloid CD11c+ conventional
DC (cDC) and the plasmacytoid DC (pDC) (Steinman and
Idoyaga, 2010; Altfeld et al., 2011). The pDC, in contrast to the
cDC, constitutively expresses TLR7 and TLR9 (Kadowaki et al.,
2001). The pDC endocytoses HIV-1 virions via Env interaction
with CD4, and the virion genomic RNA is detected by TLR7
within the endocytic compartment (Fonteneau et al., 2004;
Beignon et al., 2005; Smed-So¨rensen et al., 2005); this innate
immune detection of HIV-1 does not require viral replication
and yet results in the production of copious amounts of type 1
IFN. A clear role for the pDC in priming of naive, HIV-1-specific
CD4+ T cells has not been established, but the IFN secreted by
pDC in response to HIV-1 promotes cDC maturation and NK
cell activation (Fonteneau et al., 2004; Romagnani et al., 2005).
The complex interplay between NK cells, T cells, and DCs, as
well as the direct effects of NK cells on HIV-1-infected cells,
has been discussed extensively in a recent review (Altfeld
et al., 2011).
The importance of the cDC for priming of naive, anti-HIV-1
T cells is better established than it is for the pDC. HIV-1-pulsed,
monocyte-derived DCs, the most common experimental source
of human cDCs, prime naive CD4+ and CD8+ T cells in vitro to
generate broad, polyfunctional, anti-HIV-1 responses targeting
epitopes that mirror those detected after acute infection in vivo
(Lubong Sabado et al., 2009). Humanized mice challenged
with HIV-1 elaborate similar HIV-1-specific CD4+ and CD8+
T cell responses (Brainard et al., 2009). But, as has been well
described in HIV-1-infected people (Day et al., 2006; Trautmann
et al., 2006; Wherry et al., 2007), the HIV-1-specific T cells
elicited in these assays express elevated levels of inhibitory
molecules such as PD-1, TRAIL, and CTLA-4 that suppress the
priming of other naive T cells in a contact-dependent manner
(Brainard et al., 2009; Che et al., 2010).
In contrast to pDCs, cDCs challenged with HIV-1 do not make
type 1 IFN, and additionally, they do not produce IL-12
Figure 2. HIV-1 Virion Interaction with Dendritic Cells Is Dominated
by Nonproductive Entry Pathways
Productive infection requires that HIV-1 virions gain access to the target cell
cytoplasm via HIV-1 glycoprotein (gp120/gp41) interacting with host cell
receptors (CD4 and either CCR5 or CXCR4). Cell surface levels of CD4 are low
on many types of dendritic cells, and HIV-1 virions are endocytosed via
interaction with cell surface lectins such as DC-SIGN. Replication of the HIV-1
genomic RNA (green lines) does not occur within the endocytic compartment,
and innate immune signaling is not activated within conventional, antigen-
presenting DCs. However, the endocytosed virion is degraded, and HIV-1
proteins are therefore efficiently presented in the absence of DC maturation.
Alternatively, the glycosphingolipid GM3 in the HIV-1 virion membrane is
recognized by an unknown receptor on DCs (designated X). This results in
virion capture and transfer to susceptible CD4+ T cells via infectious synapses.
Figure 3. Bypass of the Block to Productive Entry Reveals a Block to
HIV-1 Reverse Transcription in DCs due to SAMHD1
The block to productive entry can be overcome experimentally by producing
HIV-1 virions bearing the vesicular stomatitis virus glycoprotein (VSV G). Once
in the dendritic cell cytoplasm, HIV-1 virions fail to reverse transcribe the viral
genomic RNA template (green) into viral cDNA (red), because the dNTP
concentration is too low to support cDNA synthesis. This block to reverse
transcription is due to the dNTP triphosphohydrolase SAMHD1.
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et al., 2005). The type 1 IFN produced by pDCs in response to
challenge with HIV-1 promotes cDC maturation in trans (Fonte-
neau et al., 2004), but as mentioned above, if PAMP recognition
and antigen presentation do not occur within the same cell, the
critical signals needed for full maturation of cDCs and antiviral
immunity may be lacking (Spo¨rri and Reis e Sousa, 2005; Hou
et al., 2008; Kratky et al., 2011). These observations demonstrate
that cell-intrinsic, innate immune sensing of HIV-1 is insufficient
to effect complete cDC maturation. Given the clear importance
of the cDC for T cell priming, the discussion that follows below
will focus on this DC subtype.
Nonreplicative Interactions Dominate HIV-1 Entry
into DCs
cDCs fail to mature upon HIV-1 exposure probably because
the virus cannot infect these cells (Cameron et al., 1992;
Smed-So¨rensen et al., 2005). Productive infection by HIV-1requires virion membrane fusion with the target cell membrane,
driven by the interaction between HIV-1 gp120/gp41 and the
cell surface entry receptors CD4 and CCR5. This results in
delivery of the virion core into the cytoplasm where reverse
transcription takes place (McDonald et al., 2002). Levels of cell
surface CD4 and CCR5 are relatively low on most DC subsets
(Caux et al., 1992; Granelli-Piperno et al., 2006), and when
HIV-1 encounters DCs, it is more likely to be endocytosed via
interaction with DC-SIGN or other C-type lectins (Piguet and
Steinman, 2007) (Figure 2). Reverse transcription does not occur
within this endocytic compartment, PRRs are not activated, and
DCs fail to mature (Granelli-Piperno et al., 2004).
HIV-1 virions that are endocytosed by DCs are probably trans-
ferred to a lysosomal compartment—and a fraction to protea-
somes—and rapidly degraded for processing and presentation
in the absence of DC maturation (Moris et al., 2004, 2006).
Some virions escape degradation by trafficking to immunologic
synapses, from which they are efficiently transferred to highly
permissive CD4+ T cells (Pope et al., 1994; McDonald et al.,
2003). Avoidance of the degradation pathway and transfer of
infectious virions to immunologic synapses is an Env-indepen-
dent process that requires incorporation of the host cell-
derived, glycosphingolipid GM3 into the HIV-1 virion membrane
(Izquierdo-Useros et al., 2012; Puryear et al., 2012). The
outcome of interaction with the DC C-type lectin and GM3 path-
ways would be tolerance to HIV-1 and potentiation of HIV-1
spread to highly permissive, activated CD4+ T cells (Figure 2).
Experimentally, HIV-1 virions can be pseudotyped with heter-
ologous viral glycoproteins (Figure 3). This technique can be
exploited to redirect HIV-1 transduction to cells that are normally
not targeted by HIV-1. Pseudotyping of HIV-1 with the vesicular
stomatitis virus glycoprotein (VSV G) drives fusion of HIV-1
virions from endosomes into the cytoplasm and greatlyCell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 411
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cytoplasm (Granelli-Piperno et al., 2000). This has become the
standard methodology for transducing dendritic cells with HIV-
1-based vectors (Berger et al., 2011).
SAMHD1 Prevents HIV-1 Reverse Transcription in DCs
Although VSV G pseudotyping increases the efficiency with
which HIV-1 virions enter DCs, a second block to replication
occurs at the level of reverse transcription (Figure 3). The first
clue to the nature of this block came from the observation that
viruses of the human immunodeficiency virus type 2 (HIV-2)
and the simian immunodeficiency SIVsm/SIVmac lineage are
more efficient than HIV-1 at transducing DCs and that transduc-
tion by SIVMAC vectors required the vpx accessory gene (Man-
geot et al., 2002). When provided in trans, SIV virus-like particles
(VLPs) greatly increased the efficiency of HIV-1 reverse tran-
scription and transduction in DCs (Goujon et al., 2006). This
increase in HIV-1 infectivity also required the SIV Vpx protein
(Goujon et al., 2006) andwasmimicked by proteasome inhibitors
(Goujon et al., 2007). Vpx was then shown to associate with the
CUL4A E3 ubiquitin ligase complex via direct binding to DCAF1
(Sharova et al., 2008; Srivastava et al., 2008; Bergamaschi et al.,
2009), and heterokaryon experiments demonstrated the pres-
ence of a dominant-acting inhibitor in myeloid cells that was
sensitive to Vpx (Sharova et al., 2008). The observation that
myeloid cells have 100 times lower dNTP pools than do HIV-1-
permissive, activated CD4+ T cells (Diamond et al., 2004; Ken-
nedy et al., 2010) was an additional clue to the mechanism of
the block to reverse transcription, since reverse transcription
requires dNTPs for synthesis of viral cDNA.
Vpx was then shown to promote the degradation of SAMHD1
(Goldstone et al., 2011; Powell et al., 2011; Lahouassa et al.,
2012), a triphosphohydrolase that converts deoxynucleoside
triphosphates (dNTPs) to the constituent deoxynucleosides
and inorganic triphosphate (Goldstone et al., 2011; Powell
et al., 2011; Lahouassa et al., 2012). It was reasonable to hypoth-
esize that, by depleting dNTPs, SAMHD1 would block reverse
transcription. Indeed, the kinetics of SAMHD1 degradation that
followed Vpx delivery correlated with rising dNTP levels and
subsequent increase in HIV-1 reverse transcription (Kim et al.,
2012). SAMHD1 knockdown permitted HIV-1 reverse transcrip-
tion to proceed in myeloid cells in the absence of Vpx (Hrecka
et al., 2011; Laguette et al., 2011). Cells from Aicardi-Goutie`res
Syndrome (AGS) patients that bear mutations in SAMHD1 were
similarly permissive for HIV-1 in the absence of Vpx. This inflam-
matory disease will be discussed further below. The antiviral
effect of SAMHD1 has also been reported more recently in
nondividing, resting CD4+ T cells (Baldauf et al., 2012).
Consequences of DC Transduction
Efficient HIV-1 transduction of DCs can be achieved by pseudo-
typing particles with VSV G in the presence of Vpx-bearing VLPs
or exogenous nucleosides. One group has reported that DC
maturation can occur in response to such high-efficiency trans-
duction by HIV-1 and that DC maturation was associated with
increased responsiveness of HIV-1-specific T cell clones (Manel
et al., 2010). DC maturation required interaction between the
cellular protein cyclophilin A and HIV-1 capsid protein synthe-
sized de novo from the provirus (Manel et al., 2010). Cyclophilin412 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.A is a well-characterized HIV-1 capsid-binding protein that regu-
lates HIV-1 infectivity (Sokolskaja and Luban, 2006).
Other groups have failed to detect maturation of DCs after
HIV-1 transduction (Fonteneau et al., 2004; Granelli-Piperno
et al., 2004, 2006; Beignon et al., 2005; Smed-So¨rensen et al.,
2005; Pertel et al., 2011a, 2011b), even when transduction was
pushed to high levels with Vpx. Perhaps this discrepancy is
due to variation in additional host factors that regulate HIV-1
replication in DCs, such as TREX1 (discussed below), or other
myeloid-specific, innate immune factors that are yet to be
discovered. For example, Vpx rescues HIV-1 transduction of
DCs from the antiviral state established by prior treatment with
exogenous type 1 IFN via a mechanism that is independent of
SAMHD1 and DCAF1-CUL4A (Pertel et al., 2011b).
Infection with HIV-2, a virus that expresses Vpx, is less likely to
cause AIDS than HIV-1 (de Silva et al., 2008). Perhaps by permit-
ting HIV-2 to complete reverse transcription within DCs, Vpx
enables cell-intrinsic PRRs within these cells to sense HIV-2.
Signaling from the PRRs would direct the antigen-presenting
DCs to mature and thus render acquired immune responses
against HIV-2 more effective. Consistent with this idea, polyfunc-
tional, virus-specific T cell responses are more commonly
observed with HIV-2 than with HIV-1 (Duvall et al., 2008). Further
evidence in support of this model comes from experiments in
which an HIV-1 provirus was modified to express and package
SIV Vpx; the resulting virus infected myeloid cells more efficiently
thandid theparentalHIV-1virus (Sunseri et al., 2011).Additionally,
type 1 IFN was detected in these spreading infections (Sunseri
et al., 2011), something that was not seen with wild-type HIV-1.
The correlation between Vpx and immune control is not
perfect, in that SIVMAC239, another virus that encodes Vpx, is
highly pathogenic in a nonnative hostmonkey species. However,
SIVSM, the naturally occurring virus from which SIVMAC239
was derived, is not pathogenic in its native host (Chahroudi
et al., 2012).
TREX1 Conceals HIV-1 cDNA from Detection
by the Innate Immune System
The presence of DNA in the cytoplasm of DCs and other cell
types, whether from a transfected plasmid, synthetic dsDNA,
intracellular bacteria, or infection with a DNA virus, activates
type 1 IFN (Sharma and Fitzgerald, 2011). The nuclease TREX1
was identified in a biochemical screen intended to determine
the identity of the PRR that activates type 1 IFN in response to
DNA within the cytoplasm of macrophages (Stetson et al.,
2008).However, in the follow-up functional test, TREX1disruption
did not block type 1 IFN induction by DNA, demonstrating that
TREX1wasnot the sought-after PRR.Paradoxically, TREX1-defi-
cient animals had elevated type 1 IFN and presented with inflam-
matorymyocarditis (Stetsonet al., 2008). Additionally, cDNA from
endogenous retroelements was increased in TREX1-deficient
cells, consistent with a role for TREX1 in suppressing retroviral
cDNA accumulation and blocking cell-intrinsic detection of DNA
(Stetson et al., 2008). Amazingly, reverse transcriptase inhibitors
that prevent synthesis of retroviral cDNA limited the inflammatory
disease in TREX1 null mice (Beck-Engeser et al., 2011).
Subsequently it was reported that when TREX1 is disrupted,
challenge with HIV-1 resulted in elevated levels of HIV-1 cDNA
and type 1 IFN induction (Yan et al., 2010). This study
Figure 4. The Human Exonuclease TREX1 Limits the Level of HIV-1
cDNA
HIV-1 reverse transcriptase generates a cDNA (red lines) from the HIV-1
genomic RNA (green) in the target cell cytoplasm. Normally, the HIV-1 cDNA is
not detected by pattern recognition receptors (PRRs) that recognize DNA in
the cytoplasm. When the host cell TREX1 nuclease is disrupted, either by
mutation or by siRNA, HIV-1 cDNA accumulates to supranormal levels and
activates type 1 IFN. Though several candidate receptors exist (e.g., IFI16), the
cell-intrinsic PRR that recognizes HIV-1 cDNA under these conditions has not
been identified.
Figure 5. TRIM5 Is a Pattern Recognition Receptor Specific for the
Retrovirus Capsid Lattice
The cytoplasmic E3 ubiquitin ligase TRIM5 exists as a dimer in the cytoplasm
where it signals weakly or not at all. Upon infection with a retrovirus, if avidity
for the capsid lattice is great enough, TRIM5 multimerizes to form a comple-
mentary lattice (Ganser-Pornillos et al., 2011), and E3 ubiquitin ligase activity is
increased (Pertel et al., 2011a). In complex with the heterodimeric E2 (UBC13/
UEV1A), TRIM5 synthesizes unattached K63-linked ubiquitin chains that
activate the TAK1 kinase complex and innate immune signaling (Pertel et al.,
2011a). Most HIV-1 strains (blue capsid) are only weakly detected by the
human TRIM5 ortholog. HIV-1 capsid variants that are better recognized by
human TRIM5 (orange capsid) would increase innate immune signaling and
might make better immunogens.
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Reviewdemonstrated that HIV-1 cDNA can be sensed by the innate
immune system via an intrinsic mechanism. However, the
cDNA resulting from HIV-1 reverse transcription does not
normally accumulate to sufficient levels to be detected unless
TREX1 is disrupted (Figure 4). The PRR responsible for detecting
HIV-1 cDNA under these conditions has not been determined,
although the cytosolic viral DNA sensor IFI16 is a possible candi-
date (Unterholzner et al., 2010; Sharma et al., 2011).
Mutations in the gene encoding TREX1, as well as in SAMHD1,
the HIV-1 restriction factor specific to dendritic cells, macro-
phages, and nondividing T cells, are associated with Aicardi-
Goutie`res Syndrome (AGS). This rare, lethal, inflammatory
syndrome is characterized by elevated type 1 IFN (Crow and Re-
hwinkel, 2009; Rice et al., 2009). AGS-associated mutations are
also found in genes encoding each of the three proteins that
constitute the enzyme RNASEH2 (Crow et al., 2006). This
enzyme cleaves ribonucleotides within RNA-DNA duplexes like
those found in the intermediate products of reverse transcrip-
tion. Whether RNASEH2 influences innate immune recognition
of HIV-1 in DCs remains to be determined. The current model
for AGS pathophysiology, whether due to mutations in TREX1,
SAMHD1, or RNASEH2, is that inflammation results from activa-
tion of cytosolic PRRs in response to the increased levels of
endogenous reverse transcripts or reaction intermediates that
accumulate when either of these factors is mutated. By demon-
strating that the human innate immune system is indeed capable
of detecting HIV-1, the AGS factors offer a new paradigm in AIDS
vaccine research.
TRIM5, CA-Specific Restriction, and Innate Immune
Signaling in DCs
TRIM5 was identified in expression screens seeking the factor
responsible for an anti-HIV-1 activity in diverse cell types frommacaques and owl monkeys (Sayah et al., 2004; Stremlau
et al., 2004). The TRIM5 orthologs from these two nonhuman
primates were then shown to potently block HIV-1 transduction
(10- to 100-fold). The viral determinant for sensitivity to TRIM5
restriction is the capsid protein (CA), but TRIM5 binds to the
capsid lattice, not free capsid protein (Gru¨tter and Luban,
2012) (Figure 5), and binding induces TRIM5 to form a comple-
mentary lattice (Ganser-Pornillos et al., 2011). Because the
TRIM5-CA interaction is so complicated, a robust binding
assay has not yet been developed, and conclusions about
binding strength are extrapolated from restriction activity assays
or nonquantitative, particulate association assays (Stremlau
et al., 2006).
Phylogenetic comparisons have shown that the sequences
encoding the capsid binding domain of TRIM5 are evolving at
rates faster than any coding sequence in the primate genome
(Sawyer et al., 2005). It has been suggested that this positive
selection is driven by challenges in the remote past from patho-
genic retroviruses. The human TRIM5 ortholog weakly inhibits
lab strains of HIV-1, on the order of 2-fold, in quantitative,
single-cycle infectivity assays (Sokolskaja et al., 2006; Battivelli
et al., 2010, 2011). The weak inhibition of HIV-1 by human
TRIM5 is remedied by replacing a few capsid binding residues
in the human ortholog with those from the macaque (StremlauCell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc. 413
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tion factor in vivo and that it just does not recognize lab strains of
HIV-1 very well. One group has recently cloned HIV-1 sequences
directly from infected people and found impressive variation in
TRIM5 sensitivity. Some HIV-1 isolates were ten times more
sensitive than the lab strain standard (Battivelli et al., 2010,
2011). Interestingly, the variant amino acids in these TRIM5-
sensitive strains were located in dominant CTL epitopes within
capsid, suggesting that escape from CTL forced the acquisition
of increased TRIM5 sensitivity.
TRIM5 promotes innate immune signaling (Tareen and Emer-
man, 2011; Pertel et al., 2011a) via a mechanism that involves
synthesis of unattached K63-linked ubiquitin chains and activa-
tion of the TAK1 kinase complex (Pertel et al., 2011a) (Figure 5).
This biochemical activity, and correspondingly the innate
immune signaling within DCs, was amplified greatly by infection
with retroviruses that bear restriction-sensitive capsids (Pertel
et al., 2011a). The results demonstrating that TRIM5 acts as
a PRR specific for the retrovirus capsid lattice were obtained
using select combinations of TRIM5 orthologs with specific
retrovirus capsids (Pertel et al., 2011a). For example, human
TRIM5 in DCs or macrophages signaled in response to the
restricted N-tropic MLV, but not to the isogenic, nonrestricted,
B-MLV. Owl monkey TRIM5 signaled in response to restricted
HIV-1, but not to the unrestricted SIV.
Induction of cytokines was not detected in human DCs chal-
lenged with HIV-1, most probably because the avidity of human
TRIM5 for capsid from standard strains of HIV-1 is too weak to
activate signaling. For signaling to occur in human dendritic cells
in response to HIV-1 capsid, the avidity of the interaction will
need to be increased. This might be achieved by using HIV-1
capsid variants with CTL escape mutations that confer greatly
increased HIV-1 sensitivity (Battivelli et al., 2010, 2011) (Figure 5).
Alternatively, if robust binding assays are developed for
measuring the interaction of TRIM5 with soluble capsid lattice
components (Zhao et al., 2011), screens might be undertaken
to identify small molecules that increase the avidity of the inter-
action.
Conclusions and Perspectives
HIV-1 vaccine development continues to present enormous
intellectual and technical challenges, demonstrating the ongoing
need for fundamental biological research concerning pathogen
immunity. Several well-characterized properties of HIV-1 explain
why vaccine development is so difficult. Additionally, many
observations suggest that HIV-1 detection by PRRs within DCs
is insufficient to mature antigen-presenting DCs, with the result
that naive, HIV-1-specific T cells are not primed for optimal
anti-HIV-1 immunity. Progress toward a vaccinewill likely require
that we understand how conditions can be modified such that
HIV-1 is better detected by the innate immune system. Height-
ened detection of HIV-1 by DCs would result in qualitative
improvement in T cell priming, increased survival and effector
function of anti-HIV-1 CD8+ T cells, and the requisite affinity
maturation for generation of broadly neutralizing anti-HIV-1 anti-
bodies.
Optimal T cell priming likely requires HIV-1 replication within
DCs and the resulting activation of intrinsic PRRs. A single block
to HIV-1 replication in DCs would be sufficient to preclude414 Cell Host & Microbe 12, October 18, 2012 ª2012 Elsevier Inc.a potent acquired immune response. The large number of
recently identified blocks to productive HIV-1 infection within
these cells, as discussed above, is therefore quite impressive.
Expression of DC-SIGN and low levels of CD4 on the surface
of DCs, along with GM3-glycosphingolipid within the HIV-1
virion membrane, divert HIV-1 away from productive entry path-
ways. Reverse transcription is prevented by the nucleotidase
SAMHD1. If HIV-1 cDNA is synthesized, the host nuclease
TREX1 prevents the cDNA from accumulating to levels that are
detectable by cytoplasmic PRRs. Innate immune signaling path-
ways are not activated by human TRIM5 unless CTL forces the
HIV-1 capsid to mutate such that the avidity of TRIM5 for the
capsid protein lattice is increased.
This fundamental biological information, along with technical
advances in molecular biology, offers experimental approaches
to improve DC maturation in response to HIV-1 infection. Non-
productive entry pathways can be overcome by pseudotyping
HIV-1 virionswith VSVG. dNTP levels necessary for reverse tran-
scription can be achieved by knockdown of SAMHD1, delivery of
Vpx, or deoxynucleosides. TREX1 knockdown permits HIV-1
cDNA to accumulate to sufficient levels to activate cytoplasmic
PRRs. HIV-1 capsid variants that better engage TRIM5 can
potentiate the innate immune signaling elicited by the other
measures.
It will be necessary to determine which combination of the
interventions described above allows maximal DC maturation
and requisite priming of naive anti-HIV-1 T cells. These experi-
ments could be completed in tissue culture using human blood
cells or using humanized mouse models and may provide tools
and insights that could be translated to immunize humans. For
example, autologous DCs treated ex vivo with HIV-1 vectors,
immunogens, or drugs might be reinjected as a vaccine. Simpler
vaccine formulations would of course be preferable and
will hopefully spring from the information these experiments
provide.
Going forward, valuable information that might come from
these experiments would include the identification of the PRR
recognizing HIV-1 cDNA; this PRR would be an appealing
cellular target for new adjuvant development. Other than IL-12,
what are the specific factors produced by mature, antigen-pre-
senting DCs that optimally prime naive T cells for protection
against HIV-1? What is the identity of the glycosphingolipid
GM3 receptor in DCs, and would its blockade increase the
immunogenicity of HIV-1? Would knockdown of RNASEH2,
a gene that is mutated in Aicardi-Goutie`res syndrome, increase
the level of HIV-1 reverse transcription intermediates and acti-
vate type 1 IFN, as is seen with TREX1 and HIV-1 cDNA? What
is the minimal structure of the retrovirus capsid lattice that is
recognized by TRIM5, and could this information be exploited
to improve HIV-1 CA detection by the human TRIM5 ortholog?
Ultimately, it will be of great interest to know if new vaccines
that increase the intrinsic detection of HIV-1 within antigen-pre-
senting DCs reduce the frequency of new HIV-1 infection in pop-
ulations at risk for HIV-1.ACKNOWLEDGMENTS
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